NASDAQ$STAA
STAAR Surgical Company · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
STAAR Surgical reported Q1 2026 net sales of $93.5M with net income of $5.2M and diluted EPS of $0.10.
For the quarter ended April 3, 2026, STAAR Surgical posted net sales of $93.5 million, up from $88.9 million, driven by ICL lens procedures globally. Net income was $5.2 million versus $2.8 million, with diluted EPS of $0.10 compared with $0.06. Gross margin expanded on higher volume while SG&A rose with commercial investments in key markets.
- Net sales grew to $93.5M (+5.2% YoY).
- Net income $5.2M; diluted EPS $0.10.
- ICL procedure growth in APAC and Americas.
- Gross margin improvement on manufacturing scale.
- Commercial investments support market penetration.
Headline financials
Revenue & EPS history
STAAR Surgical · Revenue · Quarterly
$93.5M
Forward guidance
STAAR does not provide quarterly EPS guidance in the 10-Q but discusses ICL adoption trends, surgeon training, and regulatory approvals in additional markets.
Tailwinds
- Revenue and EPS growth with margin expansion.
- Strong global demand for implantable collamer lenses.
Headwinds
- Higher SG&A from commercial investments.
- FX and reimbursement vary by region.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+2.4%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+3.5%
Avg return
30 days after
50%
30 / 60 earnings
Positive
+29.0%
Q1 2018
Best reaction
-24.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | +14.5% | +0.6% | |
| Q4 2025 | -1.4% | -3.2% | +6.8% | |
| Q3 2025 | -0.3% | -4.9% | -0.2% | |
| Q1 2025 | +0.2% | -2.3% | -8.1% | |
| Q4 2024 | -24.7% | -29.8% | -22.1% | |
| Q3 2024 | -4.3% | -3.8% | -3.9% | |
| Q2 2024 | +6.5% | +1.7% | -17.9% | |
| Q1 2024 | -10.8% | -7.9% | -12.0% | |
| Q4 2023 | +6.6% | +8.6% | +22.9% | |
| Q3 2023 | -13.9% | -17.5% | -21.1% | |
| Q2 2023 | -10.5% | -11.6% | -18.4% | |
| Q1 2023 | -5.8% | -1.5% | -15.9% | |
| Q4 2022 | -12.7% | -18.4% | -9.6% | |
| Q3 2022 | -18.9% | -20.0% | -14.1% | |
| Q2 2022 | +23.1% | +26.6% | +16.8% | |
| Q1 2022 | +1.9% | -9.3% | +7.6% | |
| Q4 2021 | +13.1% | +20.4% | +10.7% | |
| Q3 2021 | -1.5% | -1.3% | -24.8% | |
| Q2 2021 | +21.3% | +19.4% | +22.4% | |
| Q1 2021 | +8.6% | -8.6% | +12.6% | |
| Q4 2020 | -4.3% | -4.1% | -9.7% | |
| Q3 2020 | +2.4% | +14.8% | +7.0% | |
| Q2 2020 | -6.8% | -14.2% | -16.7% | |
| Q1 2020 | -0.5% | +3.8% | +14.8% | |
| Q4 2019 | +2.0% | +4.1% | +1.9% | |
| Q3 2019 | +14.6% | +22.1% | +28.8% | |
| Q2 2019 | +14.9% | +5.9% | -0.6% | |
| Q1 2019 | -13.3% | -16.8% | -28.7% | |
| Q4 2018 | -0.6% | -1.2% | +2.7% | |
| Q3 2018 | +10.6% | +13.9% | -1.2% | |
| Q2 2018 | +25.6% | +29.3% | +54.6% | |
| Q1 2018 | +29.0% | +38.1% | +84.8% | |
| Q4 2017 | -9.1% | -8.2% | -7.2% | |
| Q3 2017 | +12.0% | +10.5% | +17.0% | |
| Q2 2017 | -1.4% | -3.3% | +11.6% | |
| Q1 2017 | -2.9% | -3.3% | -10.0% | |
| Q4 2016 | +1.5% | -2.4% | -4.4% | |
| Q3 2016 | +9.8% | +11.6% | +28.0% | |
| Q2 2016 | +19.9% | +21.5% | +30.4% | |
| Q1 2016 | -22.4% | — | — | |
| Q4 2015 | +17.1% | — | — | |
| Q3 2015 | +13.0% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | -6.0% | — | — | |
| Q4 2013 | +10.1% | — | — | |
| Q3 2013 | -3.6% | — | — | |
| Q2 2013 | +18.6% | — | — | |
| Q1 2013 | +20.8% | — | — | |
| Q4 2012 | -5.6% | — | — | |
| Q3 2012 | +7.5% | — | — | |
| Q2 2012 | +26.3% | — | — | |
| Q1 2011 | -10.1% | — | — | |
| Q1 2012 | -0.7% | — | — | |
| Q4 2011 | -0.8% | — | — | |
| Q1 2009 | -0.8% | — | — | |
| Q3 2010 | +7.7% | — | — | |
| Q3 2011 | +7.7% | — | — | |
| Q4 2010 | -6.7% | — | — | |
| Q2 2010 | -6.7% | — | — | |
| Q2 2011 | -6.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro